Cargando…
Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
BACKGROUND: Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months. Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking. The study results of innovativ...
Autores principales: | Karivedu, Vidhya, Eldessouki, Ihab, Taftaf, Ahmad, Zhu, Zheng, Makramalla, Abouelmagd, Karim, Nagla Abdel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501230/ https://www.ncbi.nlm.nih.gov/pubmed/31179139 http://dx.doi.org/10.1155/2019/3560640 |
Ejemplares similares
-
Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
por: Karivedu, Vidhya, et al.
Publicado: (2019) -
GNQ-209P Mutation in Metastatic Uveal Melanoma and Treatment Outcome
por: Abdel Karim, Nagla, et al.
Publicado: (2018) -
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020) -
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022) -
Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Publicado: (2020)